Novo Nordisk A/S (NYSE:NVO) Shares Sold by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,708 shares of the company’s stock after selling 6,547 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Novo Nordisk A/S were worth $4,190,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. lifted its holdings in shares of Novo Nordisk A/S by 27.6% in the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after buying an additional 576 shares during the period. AQR Capital Management LLC raised its position in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Novo Nordisk A/S by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after acquiring an additional 2,817 shares during the period. Scientech Research LLC acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $467,000. Finally, Ascent Group LLC increased its holdings in shares of Novo Nordisk A/S by 19.1% in the 2nd quarter. Ascent Group LLC now owns 22,869 shares of the company’s stock valued at $3,264,000 after purchasing an additional 3,670 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $86.57 on Monday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The stock has a market cap of $388.46 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The business’s fifty day moving average price is $95.35 and its two-hundred day moving average price is $114.80. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.